Generated by AI
Zai Lab Limited ADR is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious diseases with unmet medical needs. Zai Lab Limited ADR's current portfolio centers on oncology, immunology, infectious diseases, and neuroscience, with marketed products that help address conditions such as certain cancers, autoimmune disorders, and bacterial infections. The company works through a combination of in-house research, licensing, and global collaboration to bring medicines from development into commercial use. Its product lineup includes therapies such as Zejula, Optune, Qinlock, and Nuzyra, reflecting a business model that combines innovation with ongoing commercialization across specialty healthcare markets. Zai Lab Limited ADR plays a role in the biopharmaceutical sector by supplying treatments for complex conditions where therapeutic options remain limited, serving patients, healthcare providers, and partners across China and other international markets.
WebsiteBuilding B
Pudong, 201203
China
The latest articles about ZLAB.
SHANGHAI & CAMBRIDGE, Mass., November 13, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2026:
Summary of Oct 23's posts. Generated by AI.
No summary yet.
Summary of Jul 17's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Investors talking about ZLAB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.